You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

R/R primary DLBCL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)

Not yet recruiting
  • Primary Extranodal Lymphoma
  • DLBCL
  • (no location specified)
Apr 6, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos Trial in Shanghai (Zanubrutinib, Tislelizumab)

Recruiting
  • Primary Mediastinal Large B Cell Lymphoma
  • EBV-Positive DLBCL, Nos
  • Shanghai, Shanghai, China
    Ruijin Hospital
Mar 29, 2021

Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)

Active, not recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • Ballarat, Victoria, Australia
  • +2 more
Jan 30, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Orelabrutinib + R-CHOP
  • Placebo + R-CHOP
  • Shanghai, Shanghai, China
    Shanghai Ruijing Hospital
Nov 28, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Dec 12, 2022

Including miRNA-based Tumor Signatures in Diffuse Large B Cell

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • no intervention (observational study)
  • Napoli, Italy
  • +2 more
Feb 17, 2023

Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Metabolically Armed CD19 CAR-T cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 9, 2023

Relapsed Diffuse Large B-cell Lymphoma, Refractory DLBCL Trial in Worldwide (Polatuzumab Vedotin, Mabthera, Ifosfamide)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • +4 more
  • Graz, Austria
  • +62 more
Aug 2, 2022

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 23, 2023

Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Shenyang, Liaoning, China
    Xing Xiaojing
Jun 1, 2023

Diffuse Large B-cell Lymphoma Trial in Hefei (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Metabolically Armed CD19 CAR-T cells
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Feb 9, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Diffuse Large B Cell Lymphoma Trial in Busan (PrednisoLONE 50 MG)

Completed
  • Diffuse Large B Cell Lymphoma
  • PrednisoLONE 50 MG
  • Busan, Sue-gu, Korea, Republic of
    Kosin University Gospel Hospital
Mar 31, 2022

EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)

Recruiting
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
  • Guangzhou, Guangdong, China
  • +1 more
Nov 10, 2022

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Jul 1, 2022

DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Aug 10, 2022

Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
Dec 1, 2022

Diffuse Large B-cell Lymphoma Trial in United States (Loncastuximab Tesirine, Rituximab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Reno, Nevada
  • +4 more
Jul 1, 2022

Diffuse Large B Cell Lymphoma Trial in Wuhan (Zanubrutinib plus RCHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib plus RCHOP
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 16, 2023

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023